SEC Filings

Form 10-Q
BEIGENE, LTD. filed this Form 10-Q on 11/08/2018
Document Outline
Entire Document (5299.7 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - BeiGene, Ltd.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - BEIGENE, LTD.
Page 5 - BEIGENE, LTD.
Page 6 - BEIGENE, LTD.
Page 7 - BEIGENE, LTD.
Page 8 - Use of estimates
Page 9 - Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory
Page 10 - Compensation Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Account
Page 11 - Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for
Page 12 - 3. Research and Development Collaborative Arrangements
Page 13 - 4. Business Combinations and Asset Acquisitions
Page 14 - BeiGene Pharmaceuticals (Guangzhou) Co., Ltd.
Page 15 - 7. Property and Equipment
Page 16 - 9. Land Use Right
Page 17 - 11. Income Taxes
Page 18 - 13. Long-term Bank Loans
Page 19 - 14. Shareholder Loan
Page 20 - 16. Net (Loss) Income Per Share
Page 21 - 2018 Inducement Equity Plan
Page 22 - 18. Accumulated Other Comprehensive Income (Loss)
Page 23 - 20. Shareholders Equity
Page 24 - Capital commitments
Page 25 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 26 - Recent Developments
Page 27 - Components of Operating Results
Page 28 - Selling, General and Administrative Expenses
Page 29 - Interest Expense
Page 30 - Results of Operations
Page 31 - Cost of Sales
Page 32 - Interest Income (Expense), Net
Page 33 - Cost of Sales
Page 34 - Selling, General and Administrative Expense
Page 35 - Use of Funds
Page 36 - Investing Activities
Page 37 - Contractual Obligations and Commitments
Page 38 - Debt Obligations
Page 39 - Recent Accounting Pronouncements
Page 40 - Foreign Currency Exchange Rate Risk
Page 41 - Changes in Internal Control over Financial Reporting
Page 42 - PART II. OTHER INFORMATION
Page 43 - If we encounter difficulties enrolling patients in our clinical trials, our clinical development act
Page 44 - Risks Related to Extensive Government Regulation
Page 45 - *We believe that our drug candidates designation in China as Category 1 products should confer certa
Page 46 - *The absence of patent-linkage, patent-term extension and data and market exclusivity for NMPA-appro
Page 47 - *Our drugs and any future approved drug candidates will be subject to ongoing regulatory obligations
Page 48 - *If safety, efficacy, or other issues arise with any medical product that is used in combination wit
Page 49 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain regula
Page 50 - Risks Related to Commercialization of Our Drugs and Drug Candidates
Page 51 - Our drugs and any future approved drug candidates may fail to achieve the degree of market acceptanc
Page 52 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 53 - We may explore the licensing of commercialization rights or other forms of collaboration worldwide,
Page 54 - The illegal distribution and sale by third parties of counterfeit versions of our drugs or stolen pr
Page 55 - *We will need to obtain additional financing to fund our operations, and if we are unable to obtain
Page 56 - *Fluctuations in exchange rates could result in foreign currency exchange losses and could materiall
Page 57 - Risks Related to Our Intellectual Property
Page 58 - We may not be able to protect our intellectual property rights throughout the world.
Page 59 - We may become involved in lawsuits to protect or enforce our intellectual property, which could be e
Page 60 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 61 - If we do not obtain patent term extension and data exclusivity for any drug candidates we may develo
Page 62 - We may not be successful in obtaining or maintaining necessary rights for our development pipeline t
Page 63 - We expect to rely on third parties to manufacture at least a portion of our clinical and commercial
Page 64 - If third-party manufacturers fail to comply with manufacturing regulations, our financial results an
Page 65 - We have entered into collaborations, such as with Celgene and Merck KGaA, Darmstadt Germany, and may
Page 66 - *If we fail to maintain an effective distribution channel for our products, our business and sales o
Page 67 - Risks Related to Our Industry, Business and Operations
Page 68 - *We incur significant costs as a result of operating as a public company in the United States and Ho
Page 69 - *If we fail to comply with the U.S. Foreign Corrupt Practices Act or other anti-bribery laws, our re
Page 70 - Our internal computer systems, or those used by our CROs or other contractors or consultants, may fa
Page 71 - *If we or parties on whom we rely fail to maintain the necessary licenses for the development, produ
Page 72 - We are subject to the risks of doing business globally.
Page 73 - Risks Related to Our Doing Business in the PRC
Page 74 - *There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulat
Page 75 - *We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any
Page 76 - *We may be treated as a resident enterprise for PRC tax purposes under the EIT Law and we may theref
Page 77 - *Restrictions on currency exchange may limit our ability to utilize our revenue effectively.
Page 78 - The audit report included in our Annual Report on Form 10-K filed with the SEC is prepared by audito
Page 79 - *The characteristics of the U.S. capital markets and the Hong Kong capital markets are different.
Page 80 - *Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreci
Page 81 - Your voting rights as a holder of the ADSs are limited by the terms of the deposit agreement. The de
Page 82 - *Anti-takeover provisions in our constitutional documents may discourage our acquisition by a third
Page 83 - Holders of the ADSs may be subject to limitations on transfer of their ADSs.
Page 84 - *We may be a passive foreign investment company in future taxable years, which may have adverse U.S.
Page 85 - Item 4. Mine Safety Disclosures.
Page 86 - EXHIBIT INDEX
Page 87 - SIGNATURES
Subdocument 2 - EX-10.2 - EXHIBIT 10.2
Page 1 - Exhibit 10.2
Page 2 - Issuance of Ordinary Shares
Page 3 - N/A
Subdocument 3 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer